Home › Burkitt Lymphoma › Florida
Burkitt Lymphoma clinical trials in Florida
16 studies for Burkitt Lymphoma are looking for participants at sites in Florida.
Cities in Florida
- Tampa7 studies
- Jacksonville7 studies
- St. Petersburg6 studies
- Gainesville5 studies
- West Palm Beach5 studies
- Hollywood5 studies
- Orlando5 studies
- Miami5 studies
- Pensacola4 studies
- Cape Coral3 studies
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
- University of Miami Sylvester Comprehensive Cancer Center, Miami
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07936266Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Jupiter Medical Center, Jupiter
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Golisano Children's Hospital of Southwest Florida, Fort Myers
- UF Health Cancer Institute - Gainesville, Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
- and 9 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
- Orlando Health Cancer Institute, Orlando
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- UF Health Cancer Institute - Gainesville, Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
- Nemours Children's Clinic-Jacksonville, Jacksonville
- and 8 more
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Golisano Children's Hospital of Southwest Florida, Fort Myers
- UF Health Cancer Institute - Gainesville, Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
- and 9 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Tampa
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137118Blinatumomab Consolidation in Real World
- Mayo Clinic Cancer Center, Jacksonville
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06144606Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- H. Lee Moffitt Cancer Center, Tampa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Broward Health Medical Center, Fort Lauderdale
- Golisano Children's Hospital of Southwest Florida, Fort Myers
- UF Health Cancer Institute - Gainesville, Gainesville
- and 12 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- University of Florida, Gainesville
- Nicklaus Children's Hospital, Miami
- Johns Hopkins All Children's Hospital, St. Petersburg
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.